SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+metastatic breast cancer (MBC)

Ciruelos, E. M.Pernas, S.Perello, A.Lopez, A.Salvador Bofill, F. J.Cejalvo, J. M.Blancas, I.Ponce Lorenzo, J.Servitja, S.Perez, M.Cruz, J.Albacar, C.Escriva-de-Romani, S. I.Guerra, J. A.Gonzalez-Santiago, S.Sanfeliu, E.Rodriguez, C.Tolosa, P.Ferrero-Cafiero, J. M.Prat, A.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/26153enSOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+metastatic breast cancer (MBC)conference outputopen access10.1016/j.annonc.2021.08.6151569-8041https://doi.org/10.1016/j.annonc.2021.08.615700527700311